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Abstract
The medicinal benefits of green tea (Camellia sinensis) consumption have been attributed to bioavailable polyphenols, notably
epigallocatechin gallate (EGCG). We have assessed the effects of EGCG and its non-esterified counterpart EGC on the expression
of the collagenases, matrix metalloproteinases (MMP)-1 and -13, and the stromelysin, MMP-3, in human tendon-derived
fibroblasts. Interleukin (IL)-1b increased MMP-1, -3 and -13 mRNA and output at least 30-fold. EGCG reduced this stimulation,
by 20–30% at 2.5 mM and more than 80% at 25 mM, and had a smaller effect on MMP-2 mRNA expression, which was not
stimulated by IL-1b. In all experiments EGCG was at least 10-fold more potent than EGC. EGCG reduced the stimulation of
p54 JNKySAPK phosphorylation by IL-1b but did not affect p38 MAPK phosphorylation, the degradation of IkB or the activating
phosphorylation of NFkB. We conclude that EGCG reduces the IL-1-stimulated expression of both collagenase and stromelysin
mRNA species, an effect which may be mediated by inhibition of the JNKySAPK pathway. Taken together with previous reports
of EGCG effects on the expression andyor activity of gelatinases and aggrecanases, our results underline the importance of
extracellular matrix breakdown as a potential target for the actions of green tea polyphenols.
 2004 Elsevier B.V./International Society of Matrix Biology. All rights reserved.
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1. Introduction
The reported benefits of green tea (Camellia sinensis)
consumption include anti-tumour and anti-arthritic
actions (Mukhtar and Ahmed, 2000; Dufresne and
Farnworth, 2001). These have been attributed to a family
of bioavailable polyphenols, of which epigallocatechin
gallate (EGCG) is both the most abundant and one of
the most potent in its antioxidant and biological activi-
ties (Mukhtar and Ahmed, 2000; Dufresne and Farn-
worth, 2001; Lambert and Yang, 2003); epigallocatechin
(EGC), lacking the gallate ester moiety, is substantially
Abbreviations: ADAMTS, A Disintegrin And Metalloproteinase
with ThromboSpondin motifs; Ct, threshold cycle; EGC, epigalloca-
techin; EGCG, epigallocatechin gallate; GAPDH, glyceraldehyde 3-
phosphate dehydrogenase; IL-1b, Interleukin-1b; (MT1)-MMP,
(membrane type 1)-matrix metalloproteinase.
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less active than EGCG. Several studies have indicated
that the anti-tumour activity of EGCG may correlate
with an inhibition of the expression, secretion andyor
activation of the gelatinases, matrix metalloproteinase
(MMP)-2 and MMP-9, and their activator, membrane-
type (MT)1-MMP (Annabi et al., 2002; Dell’Aica et
al., 2002; Maeda-Yamamoto et al., 2003). EGCG has
also been shown to inhibit the breakdown of both
aggrecan and collagen in a model of cartilage degrada-
tion (Adcocks et al., 2002). Aggrecan breakdown in
this system is mediated by specific aggrecanases, mem-
bers of the ADAMTS (A Disintegrin And Metallopro-
teinase with ThromboSpondin motifs) group of
metalloproteinases (Caterson et al., 2000; Tortorella et
al., 2001). The inhibition by EGCG of aggrecan break-
down may be due to a direct inhibition of these aggre-
canases, since EGCG is a selective inhibitor of
ADAMTS-1, -4 and -5, with sub-micromolar IC (Van-50
kemmelbeke et al., 2003).
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Fig. 1. Effects of EGCG and EGC on MMP mRNA expression in
tendon-derived cells. Cells were given control pretreatment (con) or
pretreated with EGC or EGCG at 2.5 or 25 mM for 18 h. IL-1b (filled
columns) or vehicle (open columns) was added and the incubation
was continued for 24 h before isolating total RNA. MMP mRNA was
normalised to GAPDH mRNA. Values for MMP-1, -3, and -13 mRNA
were expressed as a percentage of those in cells treated with IL-1b
after control pretreatment. Values for MMP-2 were expressed as a
percentage of those in control cells. Mean"S.E.M. from five inde-
pendent experiments. Significant effects of EGC or EGCG treatment
compared to the 100% values were determined from confidence inter-
vals: *P-0.05; **P-0.01; ***P-0.001.
Much less is known about the effects of the green tea
polyphenols on other MMPs, notably the collagenases,
MMP-1 and -13, and the stromelysin, MMP-3. Direct
inhibition of the collagenases by EGCG has been report-
ed (Makimura et al., 1993; Vankemmelbeke et al.,
2003), but this was only a partial effect, occurring at
concentrations two orders of magnitude higher than
those which inhibited the aggrecanases in the same
study (Vankemmelbeke et al., 2003). This suggests that
any inhibition by EGCG of collagen breakdown may
instead be due to an effect on enzyme expression or
activation. Previous evidence for effects of polyphenols
on MMP-1 expression is limited to two apparently
contradictory studies in human dermal fibroblasts:
EGCG inhibited UV-stimulated MMP-1 mRNA expres-
sion (Kim et al., 2001), whereas EGC stimulated MMP-
1 mRNA expression irrespective of UV treatment
(Soriani et al., 1998). We are interested in the patholog-
ical and pharmacological modulation of matrix turnover
in tendon (Riley et al., 1994, 2002; Corps et al., 2002)
and have now compared the effects of EGCG and EGC
on the expression of MMP-1, -2, -3 and -13 mRNA in
human tendon-derived fibroblasts stimulated with inter-
leukin (IL)-1b.
2. Results
2.1. Effects of EGCG on expression of MMPs
Tendon-derived cells expressed each of the MMP
mRNA examined. Differences between the Ct values in
the optimised semi-quantitative RT-PCR assays indicat-
ed that, in unstimulated fibroblasts, MMP-2 mRNA was
constitutively expressed at levels at least 100-fold higher
than MMP-1 or MMP-3 mRNA (i.e. a difference of
more than 7 Ct units), while the level of MMP-13
mRNA was a further 100-fold lower and close to the
detection limit (data not shown). As found previously
(Corps et al., 2002; Tzusaki et al., 2003), incubation of
tendon cells with IL-1b resulted in an increased expres-
sion of MMP-1 and MMP-3 mRNA (typically 100-fold
and 30-fold), while MMP-2 mRNA was not substantial-
ly affected (Fig. 1a–c). The level of MMP-1 and MMP-
3 mRNA in the stimulated cells was, therefore, within
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Fig. 2. Effects of EGCG and EGC on MMP secretion by tendon-
derived cells. Cells (parallel incubations to those described in Fig. 1)
were given control pretreatment (o) or pretreated with EGC or EGCG
at 2.5 or 25 mM for 18 h. IL-1b or vehicle was added and the incu-
bation was continued for 48 h, and supernatant medium was analysed
by Western blotting for (a) MMP-1, (b) MMP-2, (c) MMP-3. Similar
results were obtained in four additional experiments.
Fig. 3. Effects of EGCG on signalling responses in tendon-derived
cells. Cells were given control pretreatment (o) or pretreated with
EGCG at 2.5 or 25 mM for 18 h. IL-1b or vehicle was added and the
incubation was continued for 15 min. Cell extracts were analysed by
Western blotting for (a) phosphorylated and total p38 MAPK, and
(b) phosphorylated and total p54 JNKySAPK, as indicated. Similar
results were obtained in two additional experiments.
an order of magnitude (up to 3 Ct units) of that of
MMP-2 mRNA. MMP-13 mRNA also showed an
increase of at least 30-fold after stimulation (Fig. 1d),
but was more than 30-fold (at least 5 Ct units) lower
than the others. The ease of detection of the secreted
MMP proteins was consistent with these differences of
mRNA levels (see below).
Incubation of the cells with EGCG gave a dose-
dependent reduction in IL-1b-stimulated MMP-1, -3 and
-13 mRNA expression (Fig. 1a, c and d); typical
reductions of 20–30% in stimulation were obtained at
2.5 mM EGCG, while more than 80% reduction occurred
at 25 mM EGCG. In each experiment, EGC had either
no effect or was less potent than EGCG and, taking the
five experiments together, none of the effects of EGC
was statistically significant (Fig. 1a, c and d). MMP-2
mRNA expression was reduced by 20–40% by EGCG
at the higher dose irrespective of the presence of IL-1b
(Fig. 1b).
Consistent with the respective mRNA levels, both
MMP-1 and MMP-3 proteins were barely detectable by
Western blotting of supernatant medium from unstimu-
lated cells but were readily detected after stimulation,
while the secretion of MMP-2 was readily detected in
supernatant medium from both unstimulated and IL-1b-
stimulated cells (Fig. 2). Consistent with the much
lower level of MMP-13 mRNA, the level of MMP-13
secretion was below the detection level even after
stimulation (and is, therefore not shown). When the
cells were pretreated with 25 mM EGCG, the output of
MMP-1 and MMP-3 stimulated by IL-1b was reduced
by more than 90% (Fig. 2), while any effect of EGC
was substantially smaller. The output of MMP-2, from
control or stimulated cells, was partly reduced by 25
mM EGCG (Fig. 2). Each of MMP-1, MMP-2 and
MMP-3 were detected mainly as the proenzyme form,
with a small proportion of active MMP-1 and MMP-2;
the levels of both proenzyme and active forms were
reduced by EGCG.
2.2. Effects of EGCG on early signalling responses and
NFkB activation
EGCG has been reported to inhibit phosphorylation
responses in signalling cascades and the activation of
transcription factors (see Discussion), both of which
might affect the induction of MMP expression by IL-1.
As in other cell types, the addition of IL-1b to tendon
cells induced a rapid transient increase in phosphoryla-
tion of p38 MAPK and p54 JNKySAPK, which was
maximal at approximately 15 min (Fig. 3) and returned
to near-basal levels by 60 min (not shown). Neither
EGCG (Fig. 3a) nor EGC (not shown) affected the
stimulation of p38 MAPK phosphorylation, but EGCG
(25 mM) caused a reduction in the stimulated phospho-
rylation of p54 JNKySAPK, with no consistent effect
on the total level of p54 JNKySAPK (Fig. 3b). The
reduction in the stimulated phosphorylation of p54 JNKy
SAPK was estimated, by scanning the blots, to be
between 50 and 75%. The phosphorylation of p42yp44
ERK was neither greatly stimulated by IL-1b nor
reduced by EGCG in these cells (not shown).
The inhibitory regulator IkB, which retains the tran-
scription factor NFkB inactive in the cytoplasm,
decreased to almost undetectable levels after 15 min
incubation with IL-1b and began to increase again by
60 min (Fig. 4a). Neither EGCG (Fig. 4a) nor EGC
(not shown) affected either the decrease of IkB or its
subsequent re-appearance. In the same samples, the
phosphorylation of NFkB was reversibly stimulated by
IL-1b, and this was not affected by either EGCG (Fig.
4b) or EGC (not shown).
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Fig. 4. Effects of EGCG on NFkB activation in tendon-derived cells.
Cells were given control pretreatment (o) or pretreated with EGCG
at 2.5 or 25 mM for 18 h. IL-1b or vehicle was added and the incu-
bation was continued for 15 or 60 min. Cell extracts were analysed
by Western blotting for (a) IkB, and (b) phosphorylated and total
NFkB, as indicated. Similar results were obtained in two additional
experiments.
3. Discussion
The beneficial effects of green tea consumption may
involve actions of EGCG against matrix breakdown, by
a combination of effects on the expression and activity
of metalloproteinases. Previous studies have focussed
on the effects of EGCG on the expression of the
gelatinase MMP-2 and its activation by MT1-MMP in
cancer cells (Annabi et al., 2002; Dell’Aica et al., 2002;
Maeda-Yamamoto et al., 2003), including effects on the
expression of these genes (Annabi et al., 2002; Maeda-
Yamamoto et al., 2003). We have found that, at the
higher concentration tested, EGCG also reduced the
expression of MMP-2 in cultured tendon cells. However,
the principal novel finding of the present study is that
EGCG substantially reduced IL-1b-stimulated expres-
sion of the collagenases MMP-1 and MMP-13 and the
stromelysin MMP-3, through an inhibition of stimulated
mRNA expression (Figs. 1 and 2). EGC was substan-
tially less potent than EGCG, consistent with their
relative potency in many other systems (Mukhtar and
Ahmed, 2000; Dufresne and Farnworth, 2001).
The inhibitory effects of EGCG occurred over the
range 2.5–25 mM, which is similar to that used in
studies of various effects of EGCG on cells in vitro
(Dong et al., 1997; Nam et al., 2001; Annabi et al.,
2002; Lambert and Yang, 2003). The reported levels of
EGCG found in blood after ingestion of green tea range
up to 2 mM (Yang et al., 1998) or 5 mM (Scalbert and
Williamson, 2000). The significant effects of 2.5 mM
EGCG on the expression of MMP mRNA (typically
20–30%) are, therefore, pharmacologically relevant, and
it is also possible that higher levels of EGCG might
accumulate in the tissue. The cumulative effects over
time of partial reduction of MMP expression in vivo are
not known.
The inhibition of MMP-1 and MMP-13 expression
occurred at lower EGCG concentrations than those
required for partial inhibition of collagenase activity
(Makimura et al., 1993; Vankemmelbeke et al., 2003).
This indicates that inhibition of collagenase expression
rather than direct inhibition of enzyme activity is likely
to be a more significant effect of EGCG in preventing
tissue collagen breakdown, e.g. in cartilage (Adcocks et
al., 2002). By contrast, inhibition by EGCG of tissue
aggrecan breakdown may result principally from the
direct inhibition of aggrecanase (ADAMTS) activity,
which occurred at sub-micromolar EGCG concentrations
(Vankemmelbeke et al., 2003) and is, therefore, among
the more potent of reported responses to EGCG in vitro
(see review by Lambert and Yang, 2003). Rather higher
concentrations of EGCG (similar to those affecting
MMP expression) were required for any effect on
ADAMTS-1, -4 and -5 mRNA expression in tendon
cells or chondrocytes (ANC, unpublished data).
Although MMP-3 may contribute to proteoglycan break-
down, there are many other potential targets of MMP-3
activity (Cawston, 1998), such that inhibition of MMP-
3 expression by EGCG may have significantly wider-
ranging effects.
The regulation of MMP mRNA expression by growth
factors and cytokines (including IL-1b involves distinct
MAPK pathways leading to the activation of transcrip-
tion factors including AP-1 and NFkB, albeit with some
differences between the different MMP genes and in
different cell-types (Borden and Heller, 1997; Bond et
al., 1999; Mengshol et al., 2000; Liacini et al., 2002;
Reunanen et al., 2002). Contrasting inhibitory effects of
EGCG on particular MAPK pathways have been report-
ed (Dong et al., 1997; Maeda-Yamamoto et al., 2003;
Singh et al., 2003). In the present experiments, EGCG
had no effect on p38 MAPK or p42y44 ERK phospho-
rylation, but reduced the stimulation of p54 JNKySAPK
phosphorylation (Fig. 3); similar results have been
reported in other cell types (Dong et al., 1997; Singh et
al., 2003). The effect on p54 JNKySAPK activation
would be expected to reduce AP-1 activity, as found in
tumor-promoter-stimulated epidermal cells (Dong et al.,
1997). Taken together with previous studies indicating
the involvement of AP-1 in stimulated MMP expression
(Borden and Heller, 1997; Mengshol et al., 2000; Liacini
et al., 2002), our results indicate that inhibition of the
JNKySAPK pathway may at least partly account for the
inhibition by EGCG of MMP expression.
The transcription factor NFkB has also been shown
to be critically involved in the regulation of MMP-1,
MMP-3 and MMP-13 expression, in some cell types but
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not others (Bond et al., 1999; Mengshol et al., 2000).
Activation of NFkB involves its release from the inhib-
itory factor IkB (which is phosphorylated by IkB kinase
and targeted for destruction at the proteasome), followed
by the phosphorylation of the released NFkB. EGCG
has been reported to inhibit both the IkB kinase complex
(Yang et al., 2001) and proteasome function (Nam et
al., 2001), thus preventing IkB degradation and NFkB
activation (Kim et al., 2001; Nam et al., 2001; Yang et
al., 2001; Singh et al., 2002). However, although IL-1b
induced the expected disappearance of IkB in tendon
cells and the phosphorylation of NFkB, EGCG did not
inhibit either of these effects (Fig. 4). The difference
between this and the earlier reports may reflect the cell-
type (normal fibroblasts were more resistant than their
transformed counterparts to effects of EGCG on the
proteasome: Nam et al., 2001), or the precise conditions
used, notably the EGCG concentration or incubation
time. The results presented here were obtained using an
overnight preincubation with EGCG to ensure equilibra-
tion with intracellular targets. However, similar results
were obtained in two further experiments in which
EGCG was added together with IL-1b: again, EGCG
inhibited IL-1b-stimulated MMP expression, but did not
inhibit NFkB phosphorylation (data not shown). Our
results therefore indicate that, at least in tendon cells,
EGCG can inhibit MMP expression under conditions
where it does not inhibit the activation of NFkB.
While this paper was in preparation, Ahmed et al.
(2004) reported the inhibition by EGCG of IL-1b-
induced MMP-1 and MMP-13 in human chondrocytes.
In these cells, EGCG (20 mM) had significantly greater
inhibitory effects on the expression of MMP-13 than on
that of MMP-1, and reduced NFkB activity more mark-
edly than that of AP-1. Hence, although tendon cells
and chondrocytes both show inhibition of MMP expres-
sion by EGCG, the two studies differ in both the details
of the inhibition and the pathways involved, supporting
the suggestion (above) that there may be cell-type-
specific differences in the actions of EGCG.
While the inhibition of matrix breakdown may be
beneficial in degenerative diseases such as osteoarthritis,
or in cancer where local degradation of the matrix may
enable tumour metastasis or angiogenesis, it may be
disadvantageous elsewhere. For example, in tendon there
is histopathological, biochemical and molecular evi-
dence for a balance between the synthesis and break-
down of matrix components, which is disrupted in
patients suffering chronic tendinopathy (Kannus and
Jozsa, 1991; Riley et al., 1994, 2002); changes in MMP-
3 expression and activity have been associated with
tendon degeneration and rupture (Ireland et al., 2001;
Riley et al., 2002). Furthermore, tendon problems have
been experienced both by patients treated with broad-
spectrum metalloproteinase inhibitors (Drummond et al.,
1999), and by a proportion of patients treated with
fluoroquinolone antibiotics (Pierfitte and Royer, 1996),
which have been shown to increase the expression of
metalloproteinases in tendon cells in vitro (Williams et
al., 2000; Corps et al., 2002). We are not aware that
tendon problems have been reported as a side-effect of
green tea, but it will be of interest to observe whether
there is an increased incidence of any such problems
with its more widespread use.
4. Materials and methods
4.1. Materials
Dulbecco’s modified Eagle’s medium, fetal calf serum
(FCS) and antibiotics were obtained from Invitrogen
(Paisley, UK). EGC and EGCG were obtained from
Sigma (Poole, UK), and were freshly dissolved at 10
mM in water. IL-1b was a gift from Glaxo Wellcome
(Stevenage, UK) and aliquots (1 mgyml) were stored
at y70 8C. The anti-MMP-1 antibody was a rabbit
polyclonal antibody (Clark et al., 1992). Antibodies
against signalling kinases, NFkB and IkB were obtained
from Cell Signalling Technology (New England Biolabs,
Hitchin, UK). Other primary and secondary antibodies
were from TCS Biologicals (Buckingham, UK) and
Dako (Ely, UK), and CDP-Star detection reagent was
from Roche Diagnostics (Lewes, UK).
4.2. Cell isolation and incubation
Tendon specimens were obtained from tissue discard-
ed during surgery for chronic Achilles tendinopathy,
with informed patient consent and local ethical commit-
tee approval. Cells isolated by outgrowth from four
separate tendon explants were maintained and passaged
in DMEM containing 10% (vyv) FCS, penicillin, strep-
tomycin and 25 mM HEPES, and were used between
passages 4 and 10. Cells were seeded at 10 ywell in 6-5
well plates and were incubated for 3 days before the
experiment. They were rinsed with serum-free medium
containing insulin, transferrin and selenium, and were
incubated in 2 ml of the same medium with or without
EGCG or EGC for 18 h, before adding IL-1b (1 ngy
ml: approx 60 pM). Control cultures received equivalent
additions of medium. The cells were then incubated for
a further 24 h or 48 h, after which the medium was
removed and stored at y20 8C, and the cells were
rinsed with balanced salts solution and solubilised in
TRI-Reagent (Sigma; 1 mlywell). Parallel plates were
incubated for 15 or 60 min after the addition of IL-1b,
then placed on ice, rinsed with ice-cold balanced salts
solution and lysed in extraction buffer (10 mM Tris–
HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1 mM
EGTA, 1 mM Na VO , 50 mM NaF, 10 mM Na P O ,3 4 4 2 7
1 mM PMSF, 1 mgyml leupeptin, 1 mgyml aprotinin,
1% NP-40) for analysis of signalling proteins.
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4.3. RNA isolation and analysis by RT-PCR
RNA was isolated from the TRI-Reagent extracts by
phenol-chloroform phase separation followed by precip-
itation with isopropanol and ethanol. RNA was checked
by agarose gel electrophoresis, showing no evidence of
breakdown and no gross differences in relative levels
that would account for the changes observed with
different treatments.
RNA was assayed for GAPDH, MMP-1, -2, -3 and
-13 mRNA, using semi-quantitative RT-PCR in a
GeneAmp 5700 (Applied Biosystems, Warrington, UK).
Oligonucleotide primers were obtained from Invitrogen.
One-Step RT-PCR reagents and FAM-labelled oligonu-
cleotide probes were obtained from Applied Biosystems.
The primers and probes for GAPDH, MMP-1, -2, and
-3 have been described previously (Ireland et al., 2001).
The forward primer (F), reverse primer (R) and probe
(P) sequences for MMP-13 mRNA (amplicon 81 bp,
consisting of bp 916-996 from accession number
NM_002427) were designed using Primer Express




Each amplicon was chosen to include an intron splice
junction to prevent amplification of genomic DNA, and
BLASTn searches (www.ncbi.nlm.nih.govyBLAST)
revealed no significant similarity to other sequences. No
signal was produced if either the RNA or the reverse
transcriptase step was omitted, and each primer pair
generated a single product of the appropriate size.
Standard curves were run in each assay, using freshly-
diluted aliquots of pooled tendon cell RNA. For each
target, this produced a linear plot of threshold cycle
(Ct) against log(dilution), whose slope was within 10%
of the expected value, indicating a similar, near-maxi-
mum efficiency for each target. For each target, all RNA
samples from an experiment were assayed in duplicate
on the same plate. The values obtained for MMP mRNA
expression were normalised for GAPDH mRNA expres-
sion in the same sample. Consistent with the gel analysis
of the RNA, no treatments showed differences in
GAPDH mRNA expression that were greater than
"40% from the control cells.
4.4. Western blotting
Western blotting of MMP-1, -2 and -3 in cell culture
supernatants was performed as described previously
(Corps et al., 2002). Western blotting of signalling
kinases, IkB and NFkB in cell extracts was performed
using the primary antibodies at 1:1000, followed by
detection using alkaline phosphatase-coupled goat anti-
rabbit antibody and CDP-Star reagent (all according to
the suppliers’ recommendations).
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